Upcoming Courses
27th Annual Summer Seminars: Essential Psychopharmacology, 2016: Practice and Update
Carl Salzman, MD, Alan I. Green, MD, Russel G. Vasile, MD, Roscoe Brady, Jr., MD, PhD, Barbara J. Coffey, MD, MS
An updated review of neurobiology and brain function will be presented, taking the attendee through neurotransmission sequence from neurotransmitter and synaptic function synthesis to gene transcription. The emerging role of gene polymorphisms will be discussed as well as the interaction between genes and the environment. The current use of antipsychotic drugs and mood stabilizing drugs for the treatment of schizophrenia and bipolar disorder will be presented; new antipsychotic medications will also be discussed. New data regarding potential hazards of antipsychotic drugs will be presented. A comprehensive review of the neurobiology and genetic predisposition to depression will be emphasized along with the modern use of antidepressants based on the latest research findings. Strategies for treating resistant depression will be emphasized as well as treatment of Bipolar Depression. An overview of anxiety spectrum disorders will be presented with a focus on psychopharmacologic management. The latest advances in child and adolescent psychopharmacology will be presented. Throughout the course the establishment and importance of the therapeutic alliance when prescribing all psychotropic medications will be underscored, as will the potential hazards/benefits of polypharmacy drug interactions.
- Evaluate the latest advances in psychotropic drug treatment,
with particular emphasis on practical prescribing information; - Review/analyze psychiatric disorders and their pharmacotherapy within a framework that integrates biological and psychodynamic perspectives;
- Integrate new genetic and neurotransmission information
into prescribing practice; - Develop strategies to screen, diagnose and treat alcohol and substance abuse in patient with psychosis;
- Integrate new therapeutic trials data regarding addictive disorders, drugs during pregnancy and new side effect information;
- Effectively manage the psychopharmacologic treatment of children
and adolescents; - Integrate psychopharmacology and psychotherapy into patient care.
Additional Information
|
Monday, July 25, 2016 |
|
|
8:30-9:00 AM |
Registration |
|
9:00-10:15 AM |
Basic review of neurotransmitter and synaptic function; factors of gene expression; second and third messenger systems; neurohormones. |
|
10:15-10:30 AM |
Continental Coffee Break |
|
10:30-12:15 PM |
The “Basic Review” (continued). |
|
Tuesday, July 26, 2016 |
|
|
9:00-10:15 AM |
Biology and treatment of psychotic disorders: the new generation of antipsychotic drugs; clinical aspects of treatment: use of typical and atypical neuroleptics (including clozapine, risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole and experimental agents); Q&A. |
|
10:15-10:30 AM |
Continental Coffee Break |
|
10:30 AM-12:15 PM |
Concepts of early intervention and prevention; optimizing outcomes; treatment of alcohol and substance abuse in patients with psychosis. |
|
Wednesday, July 27, 2016 |
|
|
9:00-10:15 AM |
Overview of Depressive Disorders with a focus on psychopharmacologic management of major depression, including bipolar depression and other depressive subtypes such as psychotic depression, atypical depression and melancholia; approaches to treatment resistant depression; review of emerging treatments for depression including vagal nerve stimulation and transcranial magnetic stimulation; Q&A. |
|
10:15-10:30 AM |
Continental Coffee Break |
|
10:30 AM-12:15 PM |
Overview of Anxiety Disorders with a focus on psychopharmacological management of anxiety disorders: panic disorder, generalized anxiety disorder, obsessive compulsive disorder, phobic disorders and posttraumatic stress disorder; use of SSRIs, SNRIs, and novel neuroleptics as well as benzodiazepines; management of difficult-to-treat anxiety disorders; recent innovations in anxiety management. |
|
Thursday, July 28, 2016 |
|
|
9:00-10:15 AM |
Pharmacologic treatment of bipolar disorder: use of mood stabilizers and anticonvulsants. Q&A. |
|
10:15-10:30 AM |
Continental Coffee Break |
|
10:30 AM-12:15 PM |
Treatment algorithms and recommendations for dosing and management of adverse effects; review of pharmacokinetic and metabolic differences between adults and children. |
|
Friday, July 29, 2016 |
|
|
9:00-10:15 AM |
Diagnosis and pharmacological treatment of psychiatric disorders in children and adolescents, including ADHD, affective and anxiety disorders, tic disorders, and psychotic disorders; Q&A. |
|
10:15-10:30 AM |
Continental Coffee Break |
|
10:30 AM-12:15 PM |
Treatment algorithms and recommendations for dosing and management of adverse effects; review of pharmacokinetic and metabolic differences between adults and children. |
|
12:15 PM |
Adjourn |
Beth Israel Deaconess Department of Psychiatry Foundation, Inc./Contact Hours: 15
Accreditation:
Physicians This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of pmiCME and The Continuing Education Program at Beth Israel Deaconess Medical Center. pmiCME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION:
Weeklong Seminar: pmiCME designates the live activity for a maximum of 15 AMA PRA Category 1 Credits™
The Royal College of Physicians and Surgeons of Canada recognizes conferences and workshops held outside of Canada that are developed by a university, academy, hospital, specialty society or college as accredited group learning activities.
AMA PRA Category 1 Credits™ claimed by physicians attending live events certified and organized in the United States for AMA PRA Category 1 Credits™ can be claimed through the agreement on mutual recognition of credits between UEMS and AMA, considered as being equal to the European Continuous Medical Education Credits(ECMEC©) granted by the UEMS. One AMA PRA Category 1 Credit™ is equivalent to one (1) hour of European EACCME Credit (ECMEC©), therefore up to 15 ECMEC© Credits are available. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.
Psychologists The Continuing Education Program at Beth Israel Deaconess Medical Center, a major teaching hospital of Harvard Medical School is approved by the American Psychological Association to offer continuing education for psychologists. The Continuing Education Program at Beth Israel Deaconess Medical Center, a major teaching hospital of Harvard Medical School maintains responsibility for this program and its content.
Counselors The Continuing Education Program at Beth Israel Deaconess Medical Center, a major teaching hospital of Harvard Medical School has been approved by NBCC as an Approved Continuing Education Provider, ACEP No. 5689. Programs that do not qualify for NBCC credit are clearly identified. The Continuing Education Program at Beth Israel Deaconess Medical Center, a major teaching hospital of Harvard Medical School is solely responsible for all aspects of the programs.
Social Workers For information on the status of the application to the Massachusetts Chapter of the National Association of Social Workers, please call 617-754-1265 or email: sjruiz@bidmc.harvard.edu.
Nurses Applications have been made for the following programs to the Massachusetts Association of Registered Nurses Inc. an approved provider of nursing credits by the American Nurses Credentialing Center’s Commission on Accreditation.
Carl Salzman, MD is a Professor of Psychiatry, Harvard Medical School. He has served as Chairman, American Psychiatric Association Benzodiazepine Task Force. He has been awarded the Elvin V. Semrad Award for Outstanding Teaching in Psychiatry at the Massachusetts Mental Health Center, Vestermark Award from the American Psychiatric Association for Outstanding Contribution to Psychiatric Education, Heinz E. Lehmann Award from the New York State Department of Mental Hygiene for his contribution to psychiatric research, Teacher of the Year Award from CME and “Outstanding Psychiatrist Award for Education” by the Massachusetts Psychiatric Society. He has also been on numerous editorial boards including The American Journal of Psychiatry. Dr. Salzman is author of over 300 publications and 7 books.
Alan I. Green, MD is the Raymond Sobel Professor of Psychiatry, Professor of Pharmacology and Toxicology, and Chairman of the Department of Psychiatry at Dartmouth Medical School. An internationally recognized teacher, expert and investigator in the clinical neuropharmacology of schizophrenia and substance abuse, Dr. Green is currently the Principal Investigator of 4 NIH grants. He has published over 150 scientific articles and has received numerous awards, including the “Outstanding Psychiatrist Award for Research” from the Massachusetts Psychiatric Society and the “Outstanding Teaching Award” at the Brockton VA Medical Center.
Russell G. Vasile, MD is an Associate Professor of Psychiatry, Harvard Medical School and Director of the Affective Disorders Consultation Program at the Beth Israel Deaconess Medical Center. Dr. Vasile has published in diverse areas related to the assessment and treatment of anxiety and affective disorders. Dr. Vasile is also graduate of the Boston Psychoanalytic Society and Institute. He is a past recipient of the Elvin V. Semrad Award for Excellence in Teaching at the Massachusetts Mental Health Center.
Roscoe Brady Jr. MD, PhD is an Instructor in the Department of Psychiatry, Harvard Medical School and Director of Psychopharmacology Education at the Beth Israel Deaconess Medical Center. He is the former Director of the Neuroscience Curriculum at the Massachusetts General Hospital/McLean Hospital psychiatry residency program. His academic interests include the neurobiology of mania in bipolar disorder and his research is supported by both the Dupont-Warren and Livingston Fellowship Awards from Harvard Medical School.
Barbara J. Coffey, MD, MS is a Professor of Psychiatry and Director of Residency Education in Child and Adolescent Psychiatry, Icahn School of Medicine at Mount Sinai. She is a Professor, in the Department of Psychiatry and Research Psychiatrist at Nathan Kline Institute for Psychiatric Research; Dr. Coffey is a former Director of the Tics and Tourette’s Clinics at McLean and Massachusetts General Hospitals, and former Director of Pediatric Psychopharmacology at McLean Hospital. She is an associate editor, Advanced Pediatric Psychopharmacology and Journal of Child and Adolescent Psychopharmacology.